{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:09Z","timestamp":1793933169494,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>CGRP targeting therapies have revolutionized the migraine preventive space, introducing novel migraine-specific therapies to improve headache care. Four monoclonal antibodies (mAbs) are approved for use in prevention of episodic migraines. Erenumab (AMG334), fremanezumab (TEV48125), and galcanezumab (LY2951742) are monthly subcutaneous injections, while eptinezumab (ALD403) provides an intravenous infusion option. This review aims to examine the clinical evidence for the safety and efficacy of CGRP-targeted mAbs in the prevention of episodic migraines with a focus on recent studies (2023\u20132024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Long-term studies reveal ongoing safety and efficacy in recent literature for all 4 monoclonal antibodies. These investigations have built evidence for earlier access to CGRP treatment as they increase quality of life and reduce monthly migraine days while being better tolerated than non-specific migraine preventative therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>These studies support the recent 2024 AHS consensus statement recommending CGRP monoclonal antibodies be considered as first-line preventive treatment in episodic migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11916-025-01365-4","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:26:50Z","timestamp":1740482810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine"],"prefix":"10.1007","volume":"29","author":[{"given":"Kelly S","family":"Nicol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"1365_CR1","doi-asserted-by":"crossref","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Figures and trends from government health studies. Headache [Internet]. 2018 [cited 2024 Jul 29];58(4):496\u2013505. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29527677\/","DOI":"10.1111\/head.13281"},{"key":"1365_CR2","doi-asserted-by":"crossref","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia : An international journal of headache [Internet]. 2011 Mar [cited 2024 Jul 29];31(3):357\u201367. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20819842\/","DOI":"10.1177\/0333102410379890"},{"key":"1365_CR3","doi-asserted-by":"crossref","unstructured":"Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience [Internet]. 2010 Aug [cited 2024 Jul 29];169(2):683\u201396. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20472035\/","DOI":"10.1016\/j.neuroscience.2010.05.016"},{"key":"1365_CR4","doi-asserted-by":"crossref","unstructured":"Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neuroscience letters [Internet]. 1985 Nov 20 [cited 2024 Jul 29];62(1):131\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/2415882\/","DOI":"10.1016\/0304-3940(85)90296-4"},{"key":"1365_CR5","doi-asserted-by":"crossref","unstructured":"Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. The J Com Neurol [Internet]. 1991 [cited 2024 Jul 29];309(4):515\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1717522\/","DOI":"10.1002\/cne.903090408"},{"key":"1365_CR6","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS. The american headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain [Internet]. 2021 Jul 1 [cited 2024 Jul 31];61(7):1021\u201339. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/head.14153","DOI":"10.1111\/head.14153"},{"key":"1365_CR7","doi-asserted-by":"crossref","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain [Internet]. 2022 Dec 1 [cited 2024 Jul 29];23(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35690723\/","DOI":"10.1186\/s10194-022-01431-x"},{"key":"1365_CR8","doi-asserted-by":"crossref","unstructured":"Nagaraj K, Vandenbussche N, Goadsby P. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in episodic migraine prevention: Where do we stand today? Neurol India [Internet]. 2021 Mar 1 [cited 2024 Jul 29];69:S59\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34003149\/","DOI":"10.4103\/0028-3886.315997"},{"key":"1365_CR9","doi-asserted-by":"crossref","unstructured":"Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: Current evidence and rationale. Biodrugs [Internet]. 2022 May 1 [cited 2024 Jul 29];36(3):341. Available from: https:\/\/www.pmc\/articles\/PMC9043885\/","DOI":"10.1007\/s40259-022-00530-0"},{"key":"1365_CR10","doi-asserted-by":"crossref","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol [Internet]. 2016 Apr 1 [cited 2024 Jul 29];15(4):382\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26879279\/","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"1365_CR11","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al. A controlled trial of erenumab for episodic migraine. N Eng J Med [Internet]. 2017 Nov 30 [cited 2024 Jul 29];377(22):2123\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29171821\/","DOI":"10.1056\/NEJMoa1705848"},{"key":"1365_CR12","doi-asserted-by":"crossref","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. 2018 [cited 2024 Jul 29]; Available from: https:\/\/www.clinicaltrialsregis\/","DOI":"10.1177\/0333102418759786"},{"key":"1365_CR13","doi-asserted-by":"crossref","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet (London, England) [Internet]. 2018 Nov 24 [cited 2024 Jul 29];392(10161):2280\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30360965\/","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"1365_CR14","doi-asserted-by":"crossref","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache [Internet]. 2019 Nov 1 [cited 2024 Jul 29];59(10):1731\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31612482\/","DOI":"10.1111\/head.13652"},{"key":"1365_CR15","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al. One-year sustained efficacy of erenumab in episodic migraine: Results of the strive study. Neurology [Internet]. 2020 Aug 4 [cited 2024 Jul 29];95(5):E469\u201379. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32636324\/","DOI":"10.1212\/WNL.0000000000010019"},{"key":"1365_CR16","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, Paiva Da Silva Lima G, Hours-Zesiger P, Fernandes C et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the liberty study. Neurology [Internet]. 2021 Jun 1 [cited 2024 Jul 29];96(22):E2724\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33910942\/","DOI":"10.1212\/WNL.0000000000012029"},{"key":"1365_CR17","doi-asserted-by":"crossref","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R et al. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache [Internet]. 2021 Jun 1 [cited 2024 Jul 29];61(6):927\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34153117\/","DOI":"10.1111\/head.14138"},{"key":"1365_CR18","doi-asserted-by":"crossref","unstructured":"Wang SJ, Roxas AA, Saravia B, Kim BK, Chowdhury D, Riachi N et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia : an international journal of headache [Internet]. 2021 Nov 1 [cited 2024 Jul 29];41(13):1285\u201397. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34171973\/","DOI":"10.1177\/03331024211024160"},{"key":"1365_CR19","doi-asserted-by":"crossref","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia : an international journal of headache [Internet]. 2022 Feb 1 [cited 2024 Jul 30];42(2):108\u201318. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34743579\/","DOI":"10.1177\/03331024211053571"},{"key":"1365_CR20","doi-asserted-by":"crossref","unstructured":"Pozo-Rosich P, Dolezil D, Paemeleire K, Stepien A, Stude P, Snellman J et al. Early use of erenumab vs nonspecific oral migraine preventives: The appraise randomized clinical trial. JAMA neurology [Internet]. 2024 May 13 [cited 2024 Jul 30];81(5):461\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38526461\/","DOI":"10.1001\/jamaneurol.2024.0368"},{"key":"1365_CR21","doi-asserted-by":"crossref","unstructured":"Hershey AD, Paiva da Silva Lima G, Pannacciulli N, Mackowski M, Koukakis R, McVige JW. Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study. Clinical and translational science [Internet]. 2024 Mar 1 [cited 2024 Jul 30];17(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38476099\/","DOI":"10.1111\/cts.13755"},{"issue":"10","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"e209349","DOI":"10.1212\/WNL.0000000000209349","volume":"102","author":"U Reuter","year":"2024","unstructured":"Reuter U, Goadsby PJ, Ferrari MD, da Silva Lima GP, Mondal S, Kalim J, et al. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2\u20134 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study. Neurology. 2024;102(10):e209349.","journal-title":"Neurology."},{"key":"1365_CR23","doi-asserted-by":"crossref","unstructured":"Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol [Internet]. 2014 [cited 2024 Jul 29];13(9):885\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25127173\/","DOI":"10.1016\/S1474-4422(14)70128-0"},{"key":"1365_CR24","doi-asserted-by":"crossref","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA neurology [Internet]. 2018 Sep 1 [cited 2024 Jul 29];75(9):1080\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29813147\/","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"1365_CR25","doi-asserted-by":"crossref","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia : An international journal of headache [Internet]. 2018 Jul 1 [cited 2024 Jul 29];38(8):1442\u201354. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29848108\/","DOI":"10.1177\/0333102418779543"},{"key":"1365_CR26","doi-asserted-by":"crossref","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports [Internet]. 2020 Jul 16 [cited 2024 Jul 29];3. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/2515816320932573?icid=int.sj-full-text.citing-articles.185","DOI":"10.1177\/2515816320932573"},{"key":"1365_CR27","doi-asserted-by":"crossref","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol [Internet]. 2020 Oct 1 [cited 2024 Jul 29];19(10):814\u201325. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32949542\/","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"1365_CR28","doi-asserted-by":"crossref","unstructured":"Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: Results from the open-label period of the CONQUER trial. Advances in therapy [Internet]. 2021 Nov 1 [cited 2024 Jul 29];38(11):5465\u201383. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34542830\/","DOI":"10.1007\/s12325-021-01911-7"},{"key":"1365_CR29","doi-asserted-by":"crossref","unstructured":"Kim BK, Cho SJ, Han JH, Dell\u2019agnello G, Panni T, Kim M et al. Efficacy and safety of galcanezumab as a preventive treatment for episodic migraine in South Korean Patients: A Post-Hoc analysis of a phase 3 clinical trial. Journal of clinical neurology (Seoul, Korea) [Internet]. 2023 Sep 1 [cited 2024 Jul 29];19(5):483\u201394. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37455511\/","DOI":"10.3988\/jcn.2022.0180"},{"key":"1365_CR30","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhong L, Chowdhury D, Skorobogatykh K, Luo G, Yang X et al. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. Journal of Headache and Pain [Internet]. 2023 Dec 1 [cited 2024 Jul 29];24(1):1\u20139. Available from: https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01613-1","DOI":"10.1186\/s10194-023-01613-1"},{"key":"1365_CR31","doi-asserted-by":"crossref","unstructured":"Shibata M, Nihira A, Tanji Y, Ozeki A, Imagawa H, Komori M. Galcanezumab efficacy through the dosing interval in Japanese patients with episodic migraine: Post Hoc analysis of a phase 2 randomized trial. Neurology and Therapy [Internet]. 2023 Dec 1 [cited 2024 Jul 29];12(6):2007. Available from: https:\/\/www.pmc\/articles\/PMC10630272\/","DOI":"10.1007\/s40120-023-00534-0"},{"key":"1365_CR32","doi-asserted-by":"crossref","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache: The Journal of Head and Face Pain [Internet]. 2001 Oct 4 [cited 2024 Jul 29];41(9):854\u201361. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1526-4610.2001.01156.x","DOI":"10.1046\/j.1526-4610.2001.01156.x"},{"key":"1365_CR33","doi-asserted-by":"crossref","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. The Lancet Neurology [Internet]. 2015 Nov 1 [cited 2024 Jul 29];14(11):1081\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26432182\/","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"1365_CR34","doi-asserted-by":"crossref","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet (London, England) [Internet]. 2019 Sep 21 [cited 2024 Jul 29];394(10203):1030\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31427046\/","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"1365_CR35","doi-asserted-by":"crossref","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al. Effect of fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA [Internet]. 2018 May 15 [cited 2024 Jul 29];319(19):1999\u20132008. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29800211\/","DOI":"10.1001\/jama.2018.4853"},{"key":"1365_CR36","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology [Internet]. 2020 Nov 3 [cited 2024 Jul 29];95(18):E2487\u201399. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32913018\/","DOI":"10.1212\/WNL.0000000000010600"},{"key":"1365_CR37","doi-asserted-by":"crossref","unstructured":"Sakai F, Suzuki N, Ning X, Ishida M, Usuki C, Iba K et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: A multicenter, randomized, open-label study. Drug safety [Internet]. 2021 Dec 1 [cited 2024 Jul 29];44(12):1355\u201364. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34687446\/","DOI":"10.1007\/s40264-021-01119-2"},{"key":"1365_CR38","doi-asserted-by":"crossref","unstructured":"Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. The journal of headache and pain [Internet]. 2021 Dec 1 [cited 2024 Jul 29];22(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34246226\/","DOI":"10.1186\/s10194-021-01279-7"},{"key":"1365_CR39","doi-asserted-by":"crossref","unstructured":"Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study. Headache [Internet]. 2021 Oct 1 [cited 2024 Jul 29];61(9):1376\u201386. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34374086\/","DOI":"10.1111\/head.14196"},{"key":"1365_CR40","doi-asserted-by":"crossref","unstructured":"Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G et al. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia : an international journal of headache [Internet]. 2023 Nov 1 [cited 2024 Jul 29];43(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37987641\/","DOI":"10.1177\/03331024231214987"},{"key":"1365_CR41","doi-asserted-by":"crossref","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. The Lancet Neurology [Internet]. 2014 Nov 1 [cited 2024 Jul 29];13(11):1100\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25297013\/","DOI":"10.1016\/S1474-4422(14)70209-1"},{"key":"1365_CR42","doi-asserted-by":"crossref","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia : an international journal of headache [Internet]. 2020 Mar 1 [cited 2024 Jul 29];40(3):241\u201354. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32075406\/","DOI":"10.1177\/0333102420905132"},{"key":"1365_CR43","doi-asserted-by":"crossref","unstructured":"Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B et al. Eptinezumab for the prevention of episodic migraine: Sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther [Internet]. 2020 Dec 1 [cited 2024 Jul 29];42(12):2254\u20132265.e3. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33250209\/","DOI":"10.1016\/j.clinthera.2020.11.007"},{"key":"1365_CR44","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol [Internet]. 2023 Apr 1 [cited 2024 Jul 29];30(4):1089\u201398. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36583633\/","DOI":"10.1111\/ene.15670"},{"key":"1365_CR45","doi-asserted-by":"crossref","unstructured":"Li XN, Xu HR, Cui E, Petersen KB, Ryding J, Ettrup A et al. Pharmacokinetics and safety of eptinezumab in healthy Chinese participants: A randomized clinical trial. Clin Drug Investig [Internet]. 2023 Nov 1 [cited 2024 Jul 29];43(11):873. Available from: https:\/\/www.pmc\/articles\/PMC10632206\/","DOI":"10.1007\/s40261-023-01315-1"},{"key":"1365_CR46","doi-asserted-by":"crossref","unstructured":"Pozo-Rosich P, Ashina M, Tepper SJ, Jensen S, Boserup LP, Josiassen MK et al. Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure type: Post Hoc analyses of the DELIVER study. Neurology and therapy [Internet]. 2024 Apr 1 [cited 2024 Jul 29];13(2):339\u201353. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38236314\/","DOI":"10.1007\/s40120-023-00575-5"},{"key":"1365_CR47","doi-asserted-by":"publisher","unstructured":"Lekhalawan P, Panyarachun P, Jindasakchai P, Rattanawong W. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: A systematic review and meta-analysis of phase 3 randomized control trial. Neurol Sci. Published online April 2, 2024. https:\/\/doi.org\/10.1007\/s10072-024-07496-7","DOI":"10.1007\/s10072-024-07496-7"},{"issue":"5","key":"1365_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/head.14693","volume":"64","author":"J Robblee","year":"2024","unstructured":"Robblee J, Hakim SM, Reynolds JM, Monteith TS, Zhang N, Barad M. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials. Headache. 2024;64(5):547\u201372. https:\/\/doi.org\/10.1111\/head.14693.","journal-title":"Headache."},{"key":"1365_CR49","doi-asserted-by":"publisher","unstructured":"Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry Published online May. 2024;22. https:\/\/doi.org\/10.1136\/jnnp-2023-333295.","DOI":"10.1136\/jnnp-2023-333295"},{"key":"1365_CR50","doi-asserted-by":"crossref","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American headache society position statement update. Headache: The Journal of Head and Face Pain [Internet]. 2024 Apr 1 [cited 2024 Jul 31];64(4):333\u201341. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/head.14692","DOI":"10.1111\/head.14692"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-025-01365-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:04:08Z","timestamp":1771275848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-025-01365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s11916-025-01365-4","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing Interests and Funding - received speaking fees from AbbVie Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"55"}}